Rani Vandana, Prakash Ajit, Mannan Mohammad Amin-Ul, Das Priyanka, Haridas Hitha, Gaindaa Rajni
Department of Molecular Biology and Genetic Engineering, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India.
Department of Microbiology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Int J Mol Cell Med. 2023;12(3):242-256. doi: 10.22088/IJMCM.BUMS.12.3.242.
is the third most common cause of nosocomial infections. Linezolid (LNZ) is a reserve antibiotic recommended for infections caused by vancomycin resistant (VREfm). The aim of the present study was to investigate the prevalence of gene among linezolid resistant (LREfm) and to study the molecular epidemiology using pulse field gel electrophoresis (PFGE). Clinically significant LREfm were identified and antimicrobial susceptibility was performed by disc diffusion. Minimum inhibitory concentration (MIC) of linezolid, vancomycin, daptomycin and quinupristin/dalfopristin was determined by E-test. PCR and PCR-RFPL were performed for the detection of gene and G2576T mutation respectively. Molecular epidemiology was studied by PFGE. A total of 1081 clinically significant species were isolated which included 63.5% (n=687) and 36.5% (n=394). LREfm (30/687) were further studied. Multidrug resistance and ancomycin resistance was 100% and 80%, respectively. Linezolid MIC range was 8-256µg/ml and the most common mechanism of resistance was gene (83.3%) followed by G2576T mutation (33.3%). PFGE analysis demonstrated 4 major clones. The gene mediated linezolid resistance was high and PFGE suggests resistance was emerging in the different background strains irrespective of resistance mechanism. Studies are required to investigate factors driving the emergence of linezolid resistance. The review suggests that this is the first report of mediated resistance in from India.
是医院感染的第三大常见原因。利奈唑胺（LNZ）是一种备用抗生素，推荐用于治疗由耐万古霉素（VREfm）引起的感染。本研究的目的是调查耐利奈唑胺（LREfm）中 基因的流行情况，并使用脉冲场凝胶电泳（PFGE）研究分子流行病学。鉴定出具有临床意义的LREfm，并通过纸片扩散法进行药敏试验。通过E试验测定利奈唑胺、万古霉素、达托霉素和奎奴普丁/达福普汀的最低抑菌浓度（MIC）。分别进行PCR和PCR-RFPL检测 基因和G2576T突变。通过PFGE研究分子流行病学。共分离出1081株具有临床意义的 菌种，其中 占63.5%（n=687）， 占36.5%（n=394）。对LREfm（30/687）进行了进一步研究。多重耐药和对安普霉素耐药分别为100%和80%。利奈唑胺的MIC范围为8-256µg/ml，最常见的耐药机制是 基因（83.3%），其次是G2576T突变（33.3%）。PFGE分析显示有4个主要克隆。 基因介导的利奈唑胺耐药性很高，PFGE表明耐药性在不同背景菌株中出现，与耐药机制无关。需要开展研究来调查推动利奈唑胺耐药性出现的因素。该综述表明，这是印度关于 介导耐药性的首次报告。
